RHMD

RadioMedix is a clinical-stage biotechnology company based in Houston, Texas, specializing in the development and commercialization of targeted radiopharmaceuticals for oncology. The company focuses on both diagnostic and therapeutic applications, utilizing targeted alpha and beta-emitter therapies to treat rare and prevalent cancers. RadioMedix is well-known for its lead program, AlphaMedix, a Lead-212 labeled somatostatin analogue that has received FDA Breakthrough Therapy Designation for neuroendocrine tumors. Additionally, the company maintains a robust pipeline of radiotheranostics and has established significant partnerships with major pharmaceutical players like Sanofi and Orano Med to advance its next-generation radioligand medicines.